新マクロライド系抗生物質TMS-19-Qの変異原性

DOI
  • 園 明
    東洋醸造株式会社リサーチセンター安全性研究所
  • 小柳出 貴巳子
    東洋醸造株式会社リサーチセンター安全性研究所
  • 小林 洋四郎
    東洋醸造株式会社リサーチセンター安全性研究所
  • 山本 宏
    東洋醸造株式会社リサーチセンター安全性研究所

書誌事項

タイトル別名
  • MUTAGENICITY TESTS ON TMS-19-Q

抄録

Genetical toxicology tests on TMS-19-Q, a new macrolide antibiotic, were carried out by using microorganisms, cultured mammalian cells and small rodents.<BR>The effect of the drug on DNA damage and/or repair was examined according to the Rec-assay with Bacillus subtilis tester strains and to sister-chromatid exchange (SCE) test with cultured Chinese hamster cells.<BR>The results from these tests showed no remarkable difference in growth inhibition zones between the repair-deficient (M 45) and -proficient (H 17) tester strains, or no increase in SCE frequencies with increasing TMS-19-Q concentration; suggesting that the drug has no substantial effect on DNA damage and/or repair both in prokaryotes and eukaryotes.<BR>Further evidence for no mutagenicity of the drug was revealed by the result from the Ames microsome assay in which the drug had no effects on induction of reverse mutation.<BR>The cytogenetical effect of TMS-19-Q was examined in accordance with chromosomal aberration analysis in cultured Chinese hamster cells and with micronucleus test in mouse bone-marrow cells. Although an increase in centric fission of chromosome Nos. 10 and 11 was observed in cultured Chinese hamster cells when exposed to the drug in combination with S-9 mix., but the drug had no effect on induction of micronucleus in mice bone-marrow cells.<BR>All these results support the notion that TMS-19-Q per se is genetically safe drug.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ